News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
News BridgeBio’s $250m raise heads latest biotech financings BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloido
News Moderna jab on trial for cancer-causing syndrome Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
